Drug treatment of pediatric chronic hepatitis B

Pediatric Drugs

Volumn 4, Issue 6, 2002, Pages 361-369

  Sokal, Etienne ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA; VIRUS VACCINE;

ADULT; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED DISEASE; FLU LIKE SYNDROME; GENE MUTATION; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION; VIRUS HEPATITIS;

EID: 0036080844     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204060-00003     Document Type: Review

References (55)

1. Liver transplantation in European patients with the hepatitis B surface antigen
2. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
3. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine
4. Management of hepatitis B, 2000: Summary of a workshop
5. Clinical relevance of hepatitis B viral mutations
6. Horizontal transmission of hepatitis B virus
7. Horizontal transmission of hepatitis B from children to adoptive parents
8. Hepatitis B in a Belgian institution for mentally retarded patients: An epidemiological study
9. Molecular characterisation and sequence stability of the hepatitis B virus surface gene in children treated with interferon
10. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
11. Primary hepatocellular carcinoma and hepatitis B infection during childhood
12. Interferon-alpha-2a: A review of its pharmacological properties and therapeutic use in the management of viral hepatitis
13. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
14. Precore stop codon mutant in chronic hepatitis B virus infection in children: Its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen
15. Hepatitis B virus infection and hepatocellular carcinoma: Molecular genetics and clinical perspectives
16. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
17. Interferon-alfa treatment of chronic hepatitis B in childhood: A consensus advice based on experience in European children
18. Should chronic hepatitis B in children be treated
19. Recombinant interferon alpha 2 a hastens the rate of HBe Ag clearance in children with chronic hepatitis B
20. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial
21. Prospective, randomized controlled trial of interferon-alfa in children with chronic hepatitis B
22. Interferon alfa 2b therapy in children with chronic hepatitis B
23. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial
24. Statistical models for predicting response to interferon-alpha and spontaneous seroconversion in children with chronic hepatitis B
25. Long term follow up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
26. Long term effect of alpha interferon in children with chronic hepatitis B
27. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children
28. Update on prevention and treatment of viral hepatitis in children
29. Peginterferon alfa-2a in patients with chronic hepatitis C
30. Lamivudine as initial treatment for chronic hepatitis B in the United States
31. A dose ranging study of the pharmacokinetics, safety and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B
32. A one year trial of lamivudine for chronic hepatitis B
33. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
34. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
35. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
36. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study
37. Long term remission of chronic hepatitis B after alpha-interferon therapy
38. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: An Italian multicenter, randomized trial
39. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy
40. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation
41. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched untreated cohort
42. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
43. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
44. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
45. Lamivudine for the treatment of chronic hepatitis B
46. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
47. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
48. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
49. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
50. Current pharmacotherapy for hepatitis B infection
51. Clinical potential of emerging new agents in hepatitis B
52. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
53. No increase in demyelinating diseases after hepatitis B vaccination
54. Hepatitis B vaccination and the risk of multiple sclerosis
55. Vaccinations and the risk of relapse in multiple sclerosis